

2025 Raleigh Campus Antibigram Inpatient

GRAM POSITIVE								
Antibiogram 2025 Raleigh Campus Inpatient	*Anaerobic coverage	Enterococcus faecalis	Enterococcus faecium	Staphylococcus epidermidis	Staphylococcus lugdunensis	Staph aureus (MSSA)	Staph aureus (MRSA)	Streptococcus pneumoniae (Invasive)
Location		INPATIENTS						
# of isolates analyzed		494	47	199	37	618	530	40
		% Susceptible						
Ampicillin	*	100%	28%					
Cefotaxime- non-meningitis								98%
Cefotaxime- meningitis								95%
Ceftaroline						100%	100%	
Ceftriaxone - non-meningitis								100%
Ceftriaxone- meningitis								90%
Clindamycin	*			57%	76%	78%	71%	95%
Daptomycin		100%				100%	99%	
Erythromycin Base, Enteric	*			34%	76%	63%	9%	68%
Gentamicin Synergy (high level)		83%	91%					
Levofloxacin		83%	30%					100%
Linezolid		98%	98%	100%	100%	100%	100%	100%
Nitrofurantoin		100%	23%	100%	97%	100%	100%	
Oxacillin				32%	78%	100%	0%	
Penicillin G	*			0%	0%	0%	0%	
Penicillin G -non-meningitis								100%
Penicillin G -meningitis								74%
Streptomycin Synergy (high level)		92%	74%					
Tetracycline/Doxycycline	*			73%	89%	90%	73%	88%
Trimethoprim-sulfa				44%	92%	95%	77%	82%
Vancomycin		96%	57%	100%	100%	100%	100%	100%

This antibiogram has been prepared from SCC SOFT LIS.
 This antibiogram contains organisms isolated in 2024.
 Only the first isolate per patient is included in this data.
 * Denotes activity against anaerobes. Anaerobes are not tested for
 susceptibility profiles at WakeMed.

21 % of Inpatient MSSA are Clindamycin Inducible Resistant
 5% of Inpatient MRSA are Clindamycin Inducible Resistant

**Antibiograms are published annually for WakeMed Raleigh, WakeMed Cary and WakeMed North
 by the Microbiology Lab and the Antimicrobial Stewardship Program. 919-350-8075**

**WakeMed Health and Hospitals
 Raleigh, NC**